Entecavir May Be Superior in Lowering HBV-related Hepatitis Incidence in Lymphoma

Share this content:
Recent results on entecavir may change use of lamivudine prophylaxis in cancer patients with the hepatitis B virus.
Recent results on entecavir may change use of lamivudine prophylaxis in cancer patients with the hepatitis B virus.

In patients seropositive for hepatitis B surface antigen with diffuse large B-cell lymphoma undergoing chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), receiving the antiviral drug entecavir appears to result in a lower incidence of hepatitis B virus (HBV)-related hepatitis and HBV reactivation compared with the antiviral drug lamivudine.

Research recently reported in the Journal of the American Medical Association indicates that the rates for hepatitis B were significantly lower for patients receiving entecavir compared with lamivudine-treated patients.1

“Hepatitis B virus reactivation is a well-documented chemotherapy complication, which can lead to chemotherapy delay or premature termination and can jeopardize malignancy outcomes,” said study investigator Tongyu Lin, MD, PhD, of the Sun Yat-sen University Cancer Center in Guangzhou, China.

“This is the first prospective, randomized study comparing entecavir and lamivudine for prevention of HBV reactivation in [patients with] cancer. The incidence of HBV-associated hepatitis was significantly decreased in the entecavir group as was HBV reactivation.”

Dr. Lin and his colleagues randomly assigned 121 patients that were seropositive for the hepatitis B surface antigen with untreated diffuse large B-cell lymphoma to receive either entecavir (61 patients) or lamivudine (60 patients). The patients began etecavir or lamivudine treatment 1 week prior to the initiation of R-CHOP through 6 months after completion of chemotherapy.

RELATED: For Lymphoma Patients Receiving R-CHOP, Entecavir More Effective for HBV-Related Hepatitis Prophylaxis

The open-label, phase 3 study was conducted at 10 medical centers in China from February 2008 through December 2012. This investigation was part of a substudy of a parent study that compared a 3-week and 2-week R-CHOP chemotherapy regimen.

The research indicated that HBV-related-hepatitis occurred in 0% of patients  in the entecavir group compared to 13.3% for the lamivudine group. The HBV reactivation was 6.6% for the entecavir group compared to 30% for the lamivudine group, and delayed hepatitis B occurred in 0% in the entecavir group compared to 8.3% for the lamivudine group.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs